OakChart

DiaMedica Therapeutics Inc

DMACHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 7:00 AM ET

9.72+0.05 (0.52%)
2026-11-11 15:16 CET
Market cap
521.46 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-37.54 USD m
Free cash flow, TTM
-31.67 USD m
EPS diluted, TTM
-0.71
P/E
-
Compare

Price

DMAC against its 20, 50 and 200-day averages
2050200beatearnings
6.008.0010.00481K961KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DMACclose 9.7220-day 9.0950-day 8.11200-day 7.179.72

11.6% under 11.00 on 4 Nov 2026. Last 15 sessions, 32.7% high to low

Profile

DMAC
52-week range, 78% of the way up
5.2411.00

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

IndexRUT
Employees35
IPOJan 04, 2008
Beta0.93
ATR, 14d0.63
Rel volume0.00
Short float16.42%
Insider own43.33%
Inst own18.34%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap524.16M
Enterprise Value480.84M
Income-37.54M
Sales0.00M
Book/sh0.71
Cash/sh0.81
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees35
IPOJan 04, 2008

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B13.67
P/C12.05
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.72
Current Ratio6.72
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.71
EPS next Y-0.75
EPS next Q-0.21
EPS this Y-10.00%
EPS next Y2.92%
EPS next 5Y-9.82%
EPS past 3/5Y-10.48% 2.31%
Sales past 3/5Y- -
EPS Y/Y TTM-3.42%
Sales Y/Y TTM-
EPS Q/Q-4.97%
Sales Q/Q-
EarningsNov 12 AMC
EPS/Sales Surpr.5.43% -

Ownership

Insider Own43.33%
Insider Trans0.00%
Inst Own18.34%
Inst Trans0.95%
ROA-98.18%
ROE-114.62%
ROIC-97.75%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.98%
SMA5019.84%
SMA20035.58%
Trades-

Technical

Shs Outstand53.93M
Shs Float30.56M
Short Float16.42%
Short Ratio25.78
Short Interest5.02M
52W High11.00 -11.64%
52W Low5.24 85.32%
Volatility9.88% 7.63%
ATR (14)0.63
RSI (14)58.48
Beta0.93
Rel Volume0.00
Avg Volume194.68K
Volume2

Performance

Perf Week-9.75%
Perf Month24.30%
Perf Quarter44.00%
Perf Half Y55.27%
Perf YTD22.11%
Perf Year52.11%
Perf 3Y311.86%
Perf 5Y114.57%
Perf 10Y146.45%
Recom1.00
Target Price15.50
Prev Close9.67
Price9.72
Change %0.52%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Nov 14, 2025ResumedCCantor FitzgeraldOverweight
Oct 30, 2025InitiatedTTD CowenBuy
Oct 07, 2024InitiatedHH.C. WainwrightBuy$7-28.0%
Apr 24, 2024ResumedCCraig HallumBuy$8-17.7%
Jun 22, 2023UpgradeOOppenheimerPerform → Outperform$7-28.0%
Apr 09, 2021InitiatedOOppenheimerOutperform$27+177.8%
Feb 17, 2021InitiatedRROTH CapitalBuy$38+290.9%
Oct 30, 2020InitiatedGGuggenheimBuy$16+64.6%
Jul 08, 2020InitiatedMMaxim GroupBuy$14+44.0%
Apr 30, 2019InitiatedDDougherty & CompanyBuy$8-17.7%

Peers

Mkt cap
TickerCompanyMkt cap
MISTMilestone Pharmaceuticals Inc87.13M
VCREVicore Pharma Holding AB ADR319.62M
PROKProKidney Corp338.65M
TECXTectonic Therapeutic Inc438.26M
TENXTenax Therapeutics Inc77.35M
CALCCalciMedica Inc10.58M
TVTXTravere Therapeutics Inc4.98B
UNCYUnicycive Therapeutics Inc102.23M
CVKDCadrenal Therapeutics Inc5.15M
DWTXDogwood Therapeutics Inc47.44M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
STAHLBERG JAN10% OwnerNov 19 '25Buy7.21240,3521,732,3618,375,092Dec 08 05:15 PM
STAHLBERG JAN10% OwnerNov 21 '25Buy7.41208,8721,547,5748,712,390Dec 08 05:15 PM
STAHLBERG JAN10% OwnerNov 18 '25Buy6.75182,8821,234,6188,134,740Dec 08 05:15 PM
STAHLBERG JAN10% OwnerNov 17 '25Buy6.52187,3931,221,1657,951,858Dec 08 05:15 PM
STAHLBERG JAN10% OwnerNov 20 '25Buy7.41128,426951,2138,503,518Dec 08 05:15 PM
STAHLBERG JAN10% OwnerNov 25 '25Buy8.5773,099626,8178,825,742Dec 08 05:15 PM
STAHLBERG JAN10% OwnerNov 24 '25Buy7.8940,253317,7218,752,643Dec 08 05:15 PM
Parsons James T.DirectorNov 21 '25Option Exercise2.2012,00026,40087,854Nov 25 04:30 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B
ITWOProShares Russell 2000 High Income ETFAUM: 178.20M
URTYProShares UltraPro Russell2000 3x SharesAUM: 277.82M

News

latest 14 of 206
  • DiaMedica Heads Into Q3 Near Highs As Stroke Enrollment And Cash Runway Face Scrutiny (Earnings Whispers) -16.06%
  • DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026 (Business Wire)
  • DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial (Business Wire)
  • DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar (Business Wire)
  • DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results (Business Wire)
  • Loading…
  • DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences (Business Wire)
  • DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... (GuruFocus.com)
  • DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights (Business Wire)
  • DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 (Business Wire)
  • DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction (Business Wire) +6.62%
  • DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program (Business Wire)
  • DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.208--0.004
2026Q22026-08-10-0.190-0.201-0.1900.000.004
2026Q12026-05-06-0.190-0.186-0.1870.000.004
2025Q42026-03-30-0.170-0.180-0.1660.000.004
2025Q32025-11-12-0.170-0.160-0.1740.000.003
2025Q22025-08-12-0.180-0.190-0.1790.000.003
2025Q12025-05-13-0.180-0.180-0.1800.000.002
2024Q42025-03-17-0.180-0.173-0.1850.000.004
2024Q32024-11-13-0.150-0.155-0.1470.000.004
2024Q22024-08-07-0.130-0.157-0.1350.000.003
2024Q12024-05-08-0.140-0.157-0.1360.000.003
2023Q42024-03-19-0.120-0.140-0.1360.000.003
2023Q32023-11-13-0.120-0.127-0.1180.000.003
2023Q22023-08-14-0.160-0.177-0.1640.000.003
2023Q12023-05-15-0.200-0.160-0.1990.000.003
2022Q42023-03-28-0.140-0.140-0.1420.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.890-0.933-0.8880.000.00
2020FY-0.780-0.722-0.7840.000.00
2021FY-0.650-0.723-0.6540.000.00
2022FY-0.520-0.520-0.5170.000.00
2023FY-0.600-0.603-0.5950.000.00
2024FY-0.600-0.593-0.6050.000.00
2025FY-0.700-0.684-0.7000.000.00
2026FY--0.770--0.00
2027FY--0.748--0.00
2028FY--0.927--6.91
2029FY--0.840--24.61
2030FY--0.890--94.05

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-114000.000.000.00
2026Q3S2026-08-104000.000.000.00
2026Q3S2026-05-074000.000.000.00
2026Q3S2026-03-314000.000.000.00
2026Q3S2025-11-143000.000.000.00
2026Q3S2025-11-132000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00

Estimate history

EPS, annual-0.718-0.741-0.888-0.784-0.654-0.517-0.595-0.605-0.697-0.714
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.135-0.147-0.185-0.18-0.179-0.174-0.166-0.187-0.188
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.500000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual6.37111.95712.00718.74626.44326.44337.95842.81953.74253.926
Period201720182019202020212022202320242025MRQ
Shares, quarterly42.69342.76642.81942.85943.07252.07753.74253.88353.926
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.50
Cost of Goods Sold Incl. D&A0.050.040.040.030.030.020.020.02-
Gross Profit-0.05-0.04-0.04-0.03-0.03-0.02-0.02-0.02-
Selling, General and Administrative Excl. Other39.1734.3526.6421.2413.9813.6212.6811.576.89
Research and Development29.2824.6119.0613.117.848.778.317.904.52
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-39.23-34.40-26.68-21.27-14.00-13.65-12.70-11.59-6.40
Unusual Expense0.000.000.000.000.000.000.000.000.40
Net Income Before Taxes-37.51-32.74-24.41-19.34-13.65-13.56-12.27-10.62-5.65
Income Taxes0.030.030.030.040.030.030.030.030.08
Consolidated Net Income-37.54-32.77-24.44-19.38-13.68-13.59-12.29-10.65-5.73
Net Income From Continuing Operations-37.54-32.77-24.44-19.38-13.68-13.59-12.29-10.65-5.73
Net Income-37.54-32.77-24.44-19.38-13.68-13.59-12.29-10.65-5.73
EPS (Recurring)-0.70-0.70-0.60-0.60-0.52-0.65-0.78-0.89-0.70
EPS (Basic, Before Extraordinaries)-0.71-0.70-0.60-0.60-0.52-0.65-0.78-0.89-0.74
EPS (Diluted)-0.71-0.70-0.60-0.60-0.52-0.65-0.78-0.89-0.74
EBITDA-39.17-34.35-26.64-21.24-13.98-13.62-12.68-11.57-6.39
Non-Operating Income (Expense)1.721.662.271.930.350.080.430.971.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.212.831.651.331.191.151.350.860.46
Price To Sales Ratio--------45.07
Operating Margin---------1,280.20
Net Margin---------1,146.80
Shares Outstanding53.9353.7442.8237.9626.4426.4418.7512.0111.96
Market Capitalization521.46521.46232.19107.7941.7898.62190.0158.23457.27

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.020.000.010.010.01
Gross Profit-0.01-0.01-0.01-0.02-0.00-0.01-0.01-0.01
Selling, General and Administrative Excl. Other10.4910.479.209.028.008.138.416.87
Research and Development8.157.996.706.445.825.666.474.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.50-10.48-9.21-9.03-8.01-8.14-8.42-6.88
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-10.13-10.04-8.73-8.61-7.69-7.70-7.89-6.27
Income Taxes0.010.010.010.010.010.010.010.01
Consolidated Net Income-10.14-10.04-8.74-8.62-7.70-7.71-7.90-6.27
Net Income From Continuing Operations-10.14-10.04-8.74-8.62-7.70-7.71-7.90-6.27
Net Income-10.14-10.04-8.74-8.62-7.70-7.71-7.90-6.27
EPS (Recurring)-0.19-0.19-0.17-0.17-0.18-0.18-0.18-0.15
EPS (Basic, Before Extraordinaries)-0.19-0.19-0.17-0.17-0.18-0.18-0.18-0.15
EPS (Diluted)-0.19-0.19-0.17-0.17-0.18-0.18-0.18-0.15
EBITDA-10.49-10.47-9.20-9.02-8.00-8.13-8.41-6.87
Non-Operating Income (Expense)0.370.450.480.420.310.440.530.62
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.880.650.880.800.610.680.470.45
Shares Outstanding53.9353.8853.7452.0843.0742.8642.8242.77
Market Capitalization521.46352.56414.54355.10167.25162.42232.19179.11

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments59.8944.1552.9033.5045.1127.517.8816.821.35
Short Term Receivables0.260.240.370.080.130.340.820.780.08
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.480.230.410.250.200.070.140.370.06
Total Current Assets60.6344.6153.6733.8445.4427.928.8417.971.49
Net Property, Plant & Equipment0.340.430.480.560.110.170.220.100.04
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.401.310.000.000.000.000.000.270.27
Total Assets61.3746.3454.1634.4045.5528.099.0518.341.80
Short Term Debt Incl. Current Port. of LT Debt0.110.100.080.070.050.070.060.000.00
Accounts Payable1.480.940.930.730.511.100.180.480.51
Other Current Liabilities3.544.351.781.360.970.861.080.810.49
Total Current Liabilities5.135.392.792.171.522.031.321.301.00
Long Term Debt0.130.240.320.400.000.050.120.020.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities5.265.633.102.571.532.081.441.311.00
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity56.1140.7251.0631.8344.0226.017.6217.020.80
Total Shareholders Equity56.1140.7251.0631.8344.0226.017.6217.020.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity56.1140.7251.0631.8344.0226.017.6217.020.80
Total Liabilities & Stockholders Equity61.3746.3454.1634.4045.5528.099.0518.341.80
Book Value Per Share1.040.951.351.201.661.390.631.420.13
Tangible Book Value Per Share1.040.951.351.201.661.390.631.420.13
Full-Time Employees352819161511997
Price to Book Ratio13.604.841.941.192.247.317.6515.56-978.47
Return on Assets-60.84-48.64-43.77-34.21-36.91-66.18-77.75-56.89-231.84
Return on Equity-67.68-53.27-46.77-36.06-38.81-73.10-86.43-64.37-416.63
Return on Invested Capital-58.26-59.69-37.73-42.44-30.87-47.16-137.67-33.64-533.17
Quick Ratio11.818.2819.2715.6129.8213.776.7013.871.49
Current Ratio11.818.2819.2715.6129.8213.776.7013.871.49

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-37.24-32.77-24.44-19.38-13.68-13.59-12.29-10.65-5.73
Depreciation0.050.040.040.030.030.020.020.020.02
Other Funds (Non Cash)2.952.590.820.531.561.781.891.140.66
Funds from Operations-34.24-30.14-23.59-18.82-12.10-11.79-10.38-9.49-5.06
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.610.681.510.090.59-0.461.200.39-0.64
Cash from Operating Activities-31.63-29.46-22.08-18.73-11.51-12.25-9.19-9.10-5.70
Capital Expenditures-0.03-0.04-0.03-0.02-0.08-0.02-0.05-0.00-0.05
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.020.01-
Purchase or Sale of Investments-11.92-2.158.59-18.2811.62-20.52-16.10-3.920.00
Purchase of Investments-66.28-59.28-50.41-69.41-45.68-69.81-39.75-12.920.00
Sale Or Maturity of Investments54.3757.1359.0051.1457.3049.3023.649.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-11.95-2.198.56-18.3011.54-20.54-16.13-3.91-0.05
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock44.6744.2912.0036.850.0030.0928.850.0821.22
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock44.6744.2912.0036.850.0030.0928.850.0821.22
Proceedsfrom Stock Options43.3743.2811.7536.850.0029.8528.810.0020.57
Issuance or Reduction of Debt, Net-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.010.00
Change in Long Term Debt-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.010.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.010.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities44.6644.2811.9936.84-0.0130.0928.850.0721.22
Net Change in Cash1.0812.62-1.52-0.190.02-2.703.53-12.9415.47
Free Cash Flow-31.67-29.50-22.10-18.75-11.59-12.27-9.23-9.10-5.75
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments43.5051.3359.8955.3230.0436.32
Short Term Receivables0.240.300.260.260.160.25
Inventories0.000.000.000.000.000.00
Other Current Assets0.570.730.480.650.880.85
Total Current Assets44.3152.3660.6356.2231.0837.42
Net Property, Plant & Equipment0.290.320.340.370.390.41
Total Investments and Advances0.000.000.000.000.001.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.400.400.400.460.000.00
Total Assets45.0053.0861.3757.0531.4738.83
Short Term Debt Incl. Current Port. of LT Debt0.120.120.110.110.110.10
Accounts Payable2.813.291.481.921.261.51
Other Current Liabilities3.672.343.543.242.753.05
Total Current Liabilities6.595.755.135.274.124.67
Long Term Debt0.070.100.130.160.180.21
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities6.665.845.265.424.304.88
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity38.3447.2356.1151.6227.1733.95
Total Shareholders Equity38.3447.2356.1151.6227.1733.95
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity38.3447.2356.1151.6227.1733.95
Total Liabilities & Stockholders Equity45.0053.0861.3757.0531.4738.83
Book Value Per Share0.710.881.040.990.630.79
Tangible Book Value Per Share0.710.881.040.990.630.79
Full-Time Employees--35---
Price to Book Ratio13.606.488.0310.894.923.99
Return on Assets-98.18-76.38-60.84-58.27-67.03-61.30
Return on Equity-114.62-86.47-67.68-64.12-73.41-67.25
Return on Invested Capital-26.40-21.22-15.54-16.65-28.15-22.56
Quick Ratio6.729.1111.8110.677.558.02
Current Ratio6.729.1111.8110.677.558.02

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-10.05-10.04-8.44-8.72-7.97-7.71
Depreciation0.010.010.010.020.000.01
Other Funds (Non Cash)0.960.650.540.800.630.63
Funds from Operations-9.07-9.38-7.89-7.90-7.33-7.07
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.040.30-0.011.28-0.52-0.08
Cash from Operating Activities-8.03-9.08-7.90-6.62-7.86-7.15
Capital Expenditures-0.00-0.01-0.01-0.02-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments8.22-2.118.15-26.189.246.63
Purchase of Investments-4.64-18.90-7.39-35.35-9.79-6.87
Sale Or Maturity of Investments12.8616.7915.549.1719.0313.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities8.21-2.118.15-26.209.236.62
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.130.4211.6332.480.170.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.130.4211.6332.480.170.09
Proceedsfrom Stock Options0.000.0011.3632.010.000.00
Issuance or Reduction of Debt, Net-0.00-0.00-0.00-0.00-0.00-0.00
Change in Long Term Debt-0.00-0.00-0.00-0.00-0.00-0.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.00-0.00-0.00-0.00-0.00-0.00
Net Financing Active Other Cash Flow0.000.000.46-0.460.000.00
Other Financing Activities Uses0.000.000.46-0.460.000.00
Cash from Financing Activities0.130.4212.1032.020.170.09
Net Change in Cash0.31-10.7812.34-0.801.54-0.44
Free Cash Flow-8.04-9.09-7.91-6.63-7.86-7.16

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.42%5.0M30.6M183.96K
2026-10-1517.15%5.2M30.6M183.03K
2026-09-3018.26%5.6M30.6M181.63K
2026-09-1517.95%5.5M30.6M189.20K
2026-08-3119.91%5.4M27.1M192.30K
2026-08-1417.54%5.4M30.5M200.12K
2026-07-3119.22%5.2M27.1M206.68K
2026-07-1518.88%5.1M27.1M198.07K
2026-06-3019.23%5.2M27.1M194.02K
2026-06-1517.96%4.9M27.1M187.96K
2026-05-2917.99%4.9M27.1M191.69K
2026-05-1517.94%4.8M27.0M194.64K
2026-04-3018.17%4.9M27.0M194.29K
2026-04-1517.70%4.8M27.0M221.67K
2026-03-3117.78%4.6M25.8M221.75K
2026-03-1317.75%4.4M24.9M250.26K
2026-02-2716.63%4.1M24.9M296.29K
2026-02-1317.64%4.4M24.9M376.35K
2026-01-3014.54%4.2M28.6M401.32K
2026-01-1518.25%4.2M23.2M395.78K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.000.00-0.000.00---
call5.000.000.004.21-32.000.00---
call7.500.000.003.15-1140.00---
call10.000.000.000.73-1380.00---
call12.500.000.000.00-0.000.00---
call15.000.000.000.10-2.000.00---
put2.500.000.000.00-0.000.00---
put5.000.000.000.05-22.000.00---
put7.500.000.000.69-2.000.00---
put10.000.000.000.00-0.000.00---
put12.500.000.000.00-0.000.00---
put15.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-218-KCurrent report2026-05-20SEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-04-01ARSAnnual report to security holders. 2025-12-31SEC
2026-04-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-01DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-20SEC
2026-03-318-KCurrent report2026-03-30SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-06SCHEDULE 13G/ASEC
2026-01-064Statement of changes in beneficial ownership of securities2026-01-02SEC
2026-01-064Statement of changes in beneficial ownership of securities2026-01-02SEC
2026-01-064Statement of changes in beneficial ownership of securities2026-01-02SEC
2026-01-058-KCurrent report2026-01-05SEC
2025-12-188-KCurrent report2025-12-18SEC
2025-12-084Statement of changes in beneficial ownership of securities2025-11-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-117.63M700

Institutional holders

Manager% owned
COOPERMAN LEON G6.40%
BlackRock, Inc.4.18%
GEODE CAPITAL MANAGEMENT, LLC1.66%
MILLENNIUM MANAGEMENT LLC1.57%
STATE STREET CORP1.20%
Bleichroeder LP0.71%
VANGUARD CAPITAL MANAGEMENT LLC0.66%
OSAIC HOLDINGS, INC.0.63%
NORTHERN TRUST CORP0.61%
VANGUARD PORTFOLIO MANAGEMENT LLC0.47%

Funds

Fund% owned
iShares Russell 2000 ETF1.73%
Fidelity Small Cap Index Fund0.74%
VANGUARD EXTENDED MARKET INDEX FUND0.66%
iShares Russell 2000 Growth ETF0.64%
VANGUARD RUSSELL 2000 INDEX FUND0.39%
Fidelity Extended Market Index Fund0.29%
iShares Micro-Cap ETF0.23%
Schwab Small-Cap Index Fund0.16%
Master Small Cap Index Series0.14%
Fidelity Total Market Index Fund0.11%

OakChart. DMAC. Cached 15 minutes.